{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:40:11Z","timestamp":1783021211073,"version":"3.54.6"},"reference-count":14,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jcf.2024.05.001","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T08:46:07Z","timestamp":1715071567000},"page":"734-738","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A model for oversight of rare disease studies: The 25-year experience of the cystic fibrosis foundation data safety monitoring board"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9175-154X","authenticated-orcid":false,"given":"Lynne M.","family":"Quittell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8411-0607","authenticated-orcid":false,"given":"Richard H.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2024.05.001_bib0001","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic fibrosis","volume":"389","author":"Grasemann","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2024.05.001_bib0002","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/archpedi.1938.01980140114013","article-title":"Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathologic study","volume":"2","author":"Andersen","year":"1938","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.jcf.2024.05.001_bib0003","series-title":"Cystic fibrosis in the 20th century, people, events and progress","author":"Doershuk","year":"2001"},{"key":"10.1016\/j.jcf.2024.05.001_bib0004","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3109\/02770906809100345","article-title":"The prognosis for children with cystic fibrosis based on reasoned approaches to therapy: past, present, and future","volume":"5","author":"Warwick","year":"1968","journal-title":"J Asthma Res"},{"key":"10.1016\/j.jcf.2024.05.001_bib0005","unstructured":"Cystic Fibrosis Foundation Patient Registry 2022 Annual Data Report. Cystic Fibrosis Foundation. Bethesda, Maryland, 2023."},{"key":"10.1016\/j.jcf.2024.05.001_bib0006","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1164\/rccm.201702-0266ED","article-title":"Progress along the pathway of discovery leading to treatment and cure of cystic fibrosis","volume":"195","author":"Ramsey","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.05.001_bib0007","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0169-409X(02)00163-1","article-title":"The cystic fibrosis therapeutics development network (CF TDN): a paradigm of a clinical trials network for genetic and orphan diseases","volume":"54","author":"Goss","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jcf.2024.05.001_bib0008","series-title":"Data monitoring committees in clinical trials","author":"Ellenberg","year":"2019"},{"key":"10.1016\/j.jcf.2024.05.001_bib0009","unstructured":"Guidance for Clinical Trial Sponsors; Establishment and Operation of Clinical Trial Data Monitoring Committees, U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research (CBER) Center for Drug Evaluation and Research (CDER) Center for Devices and Radiological Health (CDRH), 2006."},{"key":"10.1016\/j.jcf.2024.05.001_bib0010","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1177\/1740774517707743","article-title":"Recommendations for data monitoring committees from the clinical trials transformation initiative","volume":"14","author":"Calis","year":"2017","journal-title":"Clin Trials"},{"key":"10.1016\/j.jcf.2024.05.001_bib0011","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jcf.2013.12.009","article-title":"A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis","volume":"13","author":"Konstan","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.05.001_bib0012","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S2213-2600(22)00504-5","article-title":"Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials","volume":"11","author":"Uluer","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2024.05.001_bib0013","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1164\/rccm.200208-855OC","article-title":"Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis","volume":"167","author":"Gibson","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.05.001_bib0014","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S2213-2600(20)30510-5","article-title":"Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for phe508del CFTR (EXTEND): an open-label extension study","volume":"9","author":"Flume","year":"2021","journal-title":"Lancet Respir Med"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:09:00Z","timestamp":1783019340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324000651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1569199324000651"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.05.001","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A model for oversight of rare disease studies: The 25-year experience of the cystic fibrosis foundation data safety monitoring board","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}